Clinical Study
Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)
Table 1
Baseline demographic and disease characteristics.
| Characteristics | Unilateral DME () | Bilateral DME () |
| Age, mean ± SD, years | 66.36 ± 9.1 | 64.69 ± 9.2 | Male (%) | 60.51 | 63.74 | Caucasians (%) | 100 | 99.34 | Baseline BCVA, mean ± SD | | | Decimal score (value/10) | 3.98 ± 2.24 | 3.56 ± 2.03 | Snellen (20/value) | 82.13 ± 84.71 | 91.95 ± 142.00 | Age at first DME diagnosis, mean ± SD, years | 63.84 ± 9.34 | 61.65 ± 9.23 | Time from DME diagnosis to study entry, mean ± SD, years | 2.57 ± 3.35 | 3.26 ± 3.11 |
|
|
BCVA, best-corrected visual acuity; DME, diabetic macular edema; SD, standard deviation.
|